PolyQ aggregation inhibitor C2-8

• UNSPSC Description:

  C2-8 is an inhibitor of polyglutamine (polyQ) aggregation (IC50s=25 and 0.05 μM for recombinant HDQ51 and in PC12 cells, respectively). It also inhibits polyQ aggregation in organotypic hippocampal slice cultures isolated from R6/2 transgenic mice and reduces neurodegeneration in a dose-dependent manner in a Drosophila model of Huntington's disease. C2-8 (100 and 200 mg/kg) reduces huntingtin aggregate size, reduces neuronal atrophy, and improves motor performance in a rotarod test in the R6/2 transgenic mouse model of Huntington's disease.

• Target Antigen:

  Huntingtin

• Type:

  Reference compound

• Related Pathways:

  Neuronal Signaling

• Field of Research:

  Others

• Assay Protocol:

  https://www.medchemexpress.com/polyq-aggregation-inhibitor-c2-8.html

• Smiles:

  O=C(NC1=CC=C(Br)C=C1)C2=CC=CC(S(=O)(NC3=CC=C(Br)C=C3)=O)=C2

• Molecular Weight:

  510.20

• References & Citations:

  [1]Zhang, et al. A potent small molecule inhibits polyglutamine aggregation in Huntington’s disease neurons and suppresses neurodegeneration in vivo. Proc. Natl. Acad. Sci. USA 102(3), 892-897 (2005).

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  300670-16-0